Coverage
-
January 26, 2026
Zenas BioPharma has asked a Massachusetts federal judge to toss a putative investor class action targeting pre-initial public offering statements about the company's spending, saying it didn't hide that it had ramped up investment in research and development.
1 other articles on this case.
View all »